Related references
Note: Only part of the references are listed.Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin
Xiufen Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2022)
Mesothelin: An Immunotherapeutic Target beyond Solid Tumors
Joshua R. Faust et al.
CANCERS (2022)
Overcoming the challenges associated with CD3+T-cell redirection in cancer
Ajit Singh et al.
BRITISH JOURNAL OF CANCER (2021)
Preclinical Characterization of HPN536, a Trispecific, T-Cell-Activating Protein Construct for the Treatment of Mesothelin-Expressing Solid Tumors
Mary Ellen Molloy et al.
CLINICAL CANCER RESEARCH (2021)
PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells
Guodi Liu et al.
HUMAN IMMUNOLOGY (2021)
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Jim Middelburg et al.
CANCERS (2021)
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
Zheng Tian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Soren Weidemann et al.
BIOMEDICINES (2021)
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
Zhenguang Wang et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2021)
The state of the art of bispecific antibodies for treating human malignancies
Shuhang Wang et al.
EMBO MOLECULAR MEDICINE (2021)
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Prasad S. Adusumilli et al.
CANCER DISCOVERY (2021)
Generation of T-cell-redirecting bispecific antibodies with differentiated profiles of cytokine release and biodistribution by CD3 affinity tuning
Lauric Haber et al.
SCIENTIFIC REPORTS (2021)
The landscape of bispecific T cell engager in cancer treatment
Shujie Zhou et al.
BIOMARKER RESEARCH (2021)
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade
Stefan Warmuth et al.
ONCOIMMUNOLOGY (2021)
A Novel T Cell-Engaging Bispecific Antibody for Treating Mesothelin-Positive Solid Tumors
Aerin Yoon et al.
BIOMOLECULES (2020)
Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors
Brendan L. Hagerty et al.
BIOMOLECULES (2020)
Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity
Johannes Sam et al.
FRONTIERS IN ONCOLOGY (2020)
A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer
Alison Crawford et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
Sebastian Kobold et al.
FRONTIERS IN ONCOLOGY (2018)
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Monika Herrmann et al.
BLOOD (2018)
Avidity-based binding to HER2 results in selective killing of HER2-overexpressing cells by anti-HER2/CD3
Dionysos Slaga et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR
Elise A. Chong et al.
BLOOD (2017)
Novel multispecific heterodimeric antibody format allowing modular assembly of variable domain fragments
Timothy J. Egan et al.
MABS (2017)
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Nan Chen et al.
ONCOIMMUNOLOGY (2017)
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
C. Krupka et al.
LEUKEMIA (2016)
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor
Jens Schreiner et al.
ONCOIMMUNOLOGY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Raffit Hassan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins
Prince Awuah et al.
MOLECULAR CANCER THERAPEUTICS (2016)
CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1
Takuya Osada et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab
Thomas Koehnke et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
G. S. Laszlo et al.
BLOOD CANCER JOURNAL (2015)
High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis
Anish Thomas et al.
ONCOTARGET (2015)
Discovery of Mesothelin and Exploiting It as a Target for Immunotherapy
Ira Pastan et al.
CANCER RESEARCH (2014)
Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma
Stefan S. Kachala et al.
CLINICAL CANCER RESEARCH (2014)
Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival
Gary Tozbikian et al.
PLOS ONE (2014)
A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers
Jordan M. Winter et al.
PLOS ONE (2012)
Cytotoxic Activity of Immunotoxin SS1P Is Modulated by TACE-Dependent Mesothelin Shedding
Yujian Zhang et al.
CANCER RESEARCH (2011)
Share Paper
